Can we safely restrict transfusion in trauma patients?

Current Opinion in Critical Care

Volumn 12, Issue 6, 2006, Pages 575-583

  McIntyre, Lauralyn A ^a,b   Hebert, Paul C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b Department of Medicine ^*  (Canada)

Author keywords

Red blood cells; Transfusion; Trauma

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 7; HEMOSTATIC AGENT;

BLEEDING; BLOOD TRANSFUSION REACTION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SAFETY; EMERGENCY CARE; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HOSPITAL CARE; HUMAN; INFECTION RISK; INJURY; INTENSIVE CARE UNIT; META ANALYSIS; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY;

BLOOD SUBSTITUTES; BLOOD TRANSFUSION; CRITICAL CARE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEMOSTATICS; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MULTIPLE ORGAN FAILURE; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; WOUNDS AND INJURIES;

EID: 33750592638     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32801067f0     Document Type: Review

References (115)

1. Moore FA, McKinley BA, Moore EE. The next generation in shock resuscitation. Lancet 2004; 363:1988-1996.
2. Shires T. Fluid therapy in hemorrhagic shock. Arch Surg 1964; 88:688-693.
3. Dillon J, Lynch LJ Jr, Myers R, et al. A bioassay of treatment of hemorrhagic shock. I. The roles of blood, Ringer's solution with lactate, and macromolecules (dextran and hydroxyethyl starch) in the treatment of hemorrhagic shock in the anesthetized dog. Arch Surg 1966; 93:537-555.
4. Cervera AL, Moss G. Progressive hypovolemia leading to shock after continuous hemorrhage and 3:1 crystalloid replacement. Am J Surg 1975; 129:670-674.
5. American College of Surgeons Committee on Trauma. Advanced trauma life support course. Chicago: American College of Surgeons; 1989.
6. Goodnough LT. Anemia, transfusion and mortality. N Engl J Med 2001; 345:1272-1274.
7. Velmahos GC, Chan L, Chan M, et al. Is there a limit to massive blood transfusion after severe trauma? Arch Surg 1998; 133:947-952.
8. Hamilton SM. The use of blood in resuscitation of the trauma patient. Can J Surg 1993; 36:21-27.
9. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth 2000; 85:487-491.
10. Phillips GR, Kauder DR, Schwab CW. Massive blood loss in trauma patients. The benefits and dangers of transfusion therapy. Postgrad Med 1994; 95:61-62.
11. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417.
12. Henry S, Scalea TM. Resuscitation in the new millennium. Surg Clin North Am 1999; 79:1259-1267.
13. Ronco JJ, Fenwick JC, Tweeddale MG. Does increasing oxygen delivery improve outcome in the critically ill? Crit Care Clin 1996; 12:645-659.
14. Hebert PC, Hu LQ, Biro GP. Review of physiologic mechanisms in response to anemia. Can Med Assoc J 1997; 156:S27-S40.
15. Rixen D, Raum M, Bouillon B, et al., of the Deutsche Gesellschaft fur Unfallchirurgie. Base deficit development and its prognostic significance in posttrauma critical illness: an analysis by the trauma registry of the Deutsche Gesellschaft fur Unfallchirurgie. Shock 2001; 15:83-89.
16. Blajchman MA. Incidence and significance of the bacterial contamination of blood components. Dev Biol (Basel) 2002; 108:59-67.
17. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17:120-162.
18. Dodd RY, Notari EP IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975-979.
19. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454-462.
20. Brecher M. Technical manual. Bethesda: American Association of Blood Banks; 2003.
21. Chang H, Hall GA, Geerts WH, et al. Allogeneic red blood cell transfusion is an independent risk factor for the development of postoperative bacterial infection. Vox Sang 2000; 78:13-18.
22. Hill GE, Frawley WH, Griffith KE, et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 2003; 54:908-914.
23. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39:665-670.
24. Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells. Transfusion 1999; 39:701-710.
25. Messmer KF. Acceptable hematocrit levels in surgical patients. World J Surg 1987; 11:41-46.
26. Tinmouth A, Chin-Yee I. The clinical consequences of the red cell storage lesion. Transfus Med Rev 2001; 15:91-107.
27. Deitch EA, Goodman ER. Prevention of multiple organ failure. Surg Clin North Am 1999; 79:1471-1488.
28. Moore FA, Sauaia A, Moore EE, et al. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma 1996; 40:501-512.
29. Lee CC, Marill KA, Carter WA, Crupi RS. A current concept of trauma-induced multiorgan failure. Ann Emerg Med 2001; 38:170-176.
30. Moore FA, Moore EE, Read RA. Postinjury multiple organ failure: role of extrathoracic injury and sepsis in adult respiratory distress syndrome. New Horizons 1993; 1:538-549.
31. Saadia R, Schein M. Multiple organ failure. How valid is the 'two hit' model? J Accid Emerg Med 1999; 16:163-166.
32. Moore FA, Moore EE, Sauaia A. Blood transfusion - an independent risk factor for postinjury multiple organ failure. Arch Surg 1997; 132:620-625.
33. Sauaia A, Moore FA, Moore EE, et al. Multiple organ failure can be predicted as early as 12 h after injury. J Trauma 1998; 45:291-301.
34. Sauaia A, Moore FA, Moore EE, et al. Early predictors of postinjury multiple organ failure. Arch Surg 1994; 129:39-45.
35. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. J Surg 1999; 178:570-572.
36. Aiboshi J, Moore EE, Ciesla DJ, Silliman CC. Blood transfusion and the two-insult model of postinjury multiple organ failure. Shock 2001; 15:302-306.
37. Ogura H, Tanaka H, Koh T, et al. Priming, second-hit priming, and apoptosis in leukocytes from trauma patients. J Trauma 1999; 46:774-781.
38. Botha AJ, Moore FA, Moore EE, et al. Postinjury neutrophil priming and activation: an early vulnerable window. Surgery 1995; 118:358-364.
39. Biffl WL, Moore EE, Offner PJ, et al. Plasma from aged stored red blood cells delays neutrophil apoptosis and primes for cytotoxicity: abrogation by poststorage washing but not prestorage leukoreduction. J Trauma 2001; 50:426-431.
40. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289:1941-1949.
41. Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leuko-reduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth 2004; 51:417-424.
42. Hebert PC, Chin-Yee I. Clinical consequences of prolonged blood storage: should old red cells be transfused in critically ill patients? Transfus Altern Transfus Med 2001; 3:19-25.
43. Hebert PC, Chin-Yee I, Fergusson DA, et al. A pilot trial evaluating the clinical effects of prolonged storage of red cell. Anesth Analg 2005; 100:1433-1438.
44. Walsh TS, McArdle F, McLellan SA, et al. Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? Crit Care Med 2004; 32:364-371.
45. Hebert PC, Wells G, Martin C, et al. A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. Crit Care Med 1998; 26:482-487.
46. Hebert PC, Fergusson DA, Stather D, et al. Revisiting transfusion practices in critically ill patients. Crit Care Med 2005; 33:7-12. This Canadian survey of critical care physicians describes how stated transfusion practices have changed over time using four hypothetical and applicable scenarios in the critically ill.
47. Calder L, Hebert PC, Carter AO, Graham ID. Review of published recommendations and guidelines for the transfusion of allogeneic red blood cells and plasma. Can Med Assoc J 1997; 156:S1-S8.
48. Hebert PC, Wells G, Martin C, et al. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Crit Care (London) 1999; 3:57-63.
49. Farion KJ, McLellan BA, Boulanger BR, Szalai JP. Changes in red cell transfusion practice among adult trauma victims. J Trauma 1998; 44:583-587.
50. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004; 32:39-52.
51. Vincent JL, Baron J-F, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507.
52. Fowler RA, Berenson M. Blood conservation in the intensive care unit. Crit Care Med 2003; 31 (12 Suppl):S715-S720.
53. Corwin HL. Blood conservation in the critically ill patient. Anesth Clin N Am 2005; 23:363-372. This review article summarizes the competing risks and benefits of RBC transfusions, large multicenter observational studies describing current transfusion practices, as well as some blood conservation strategies.
54. Tremblay LN, Rizoli SB, Brenneman FD. Advances in fluid resuscitation of hemorrhagic shock. Can J Surg 2001; 44:172-179.
55. Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des 2005; 11:4099-4114. This article provides a review of the rationale for oxygen carriers (hemoglobin based and perfluorocarbon emulsions) by summarizing both the clinical and laboratory evidence.
56. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288:2827-2835.
57. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350.
58. Coats T, Roberts I, Shakur H. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2006; 4. This article summarizes the current and sparse evidence for use of antifibrinolytics in the trauma population.
59. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8-15. This article is important because it is the only published randomized controlled trial that has examined use of FVIIa in blunt and penetrating trauma.
60. Huet C, Salmi LR, Fergusson D, et al. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth Analg 1999; 89:861-869.
61. Henry ML, Garner WL, Fabri PJ. Iatrogenic anemia. Am J Surg 1986; 151:362-363.
62. Foulke GE, Harlow DJ. Effective measures for reducing blood loss from diagnostic laboratory tests in intensive care unit patients. Crit Care Med 1989; 17:1143-1145.
63. Smoller BR, Kurskall MS, Horowitz GL. Reducing adult phlebotomy blood loss with the use of pediatric sized blood collection tubes. Am J Clin Pathol 1989; 91:701-703.
64. Salem M, Chernow B, Burke R, et al. Bedside diagnostic blood testing. Its accuracy, rapidity, and utility in blood conservation. JAMA 1991; 266:382-389.
65. Alex CP, Manto JC, Garland JS. Clinical utility of a bedside blood analyzer for measuring blood chemistry values in neonates. J Perinatol 1998; 18:45-48.
66. Gleason E, Grossman S, Campbell C. Minimizing diagnostic blood loss in critically ill patients. Am J Crit Care 1992; 1:85-90.
67. Preusser BA, Lash J, Stone KS, et al. Quantifying the minimum discard sample required for accurate arterial blood gases. Nurs Res 1989; 38:276-279.
68. Moore EE, Cheng AM, Moore HB, et al. Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehospital trial. World J Surg 2006; 30:1-11. This important article summarizes the current level of evidence for hemoglobin-based oxygen carriers in trauma. It provides the scientific rationale for a current trial after a previous study was stopped prematurely due to excess mortality seen in the hemoglobin-based oxygen carrier group.
69. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282:1857-1864.
70. Wettstein R, Cabrales P, Erni D, et al. Resuscitation from hemorrhagic shock with MalPEG-albumin: comparison with MalPEG-hemoglobin. Shock 2004; 22:351-357.
71. Boura C, Caron A, Longrois D, et al. Volume expansion with modified hemoglobin solution, colloids, or crystalloid after hemorrhagic shock in rabbits: effects in skeletal muscle oxygen pressure and use versus arterial blood velocity and resistance. Shock 1919; (2):176-182.
72. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998; 187:113-120; discussion 120-122.
73. Gould SA, Moore EE, Moore FA, et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma 1997; 43:325-331; discussion 331-332.
74. Johnson JL, Moore EE, Offner PJ, et al. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am J Surg 1998; 176:612-617.
75. Jenkinson SG. Oxygen toxicity. New Horizons 1993; 1:504-511.
76. Corwin HL. The role of erythropoietin therapy in the critically ill. Transfus Med Rev 2006; 20:27-33. This important article summarizes the current level of evidence for erythropoietin use in the critically ill and provides the rationale for additional clinical research in this area.
77. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
78. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. Transfus Med 1998; 8:309-317.
79. Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999; 9:21-30.
80. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005; 33:497-503. This study is the only published cost-effectiveness analysis of erythropoietin use in the critically ill.
81. Corwin HL, Hebert P. Avoiding a blood transfusion: how much is it worth? Crit Care Med 2005; 33:672-674. This editorial provides an excellent critical review of the cost effectiveness analysis of erythropoietin by Shermock et al. [80•].
82. Hughes LG, Thomas DW, Wareham K, et al. Intra-operative blood salvage in abdominal trauma: a review of 5 years' experience. Anaesthesia 2001; 56:217-220.
83. Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage. A large randomised placebo controlled trial among trauma patients with, or at risk of, significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement. London: London School of Hygiene & Tropical Medicine; 2006. http://www.crash2.lshtm.ac.uk/.
84. Holcomb JB. Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma. J Trauma 2005; 58:1298-1303. This article provides a review of the laboratory and clinical evidence of FVIIa use in trauma.
85. Barletta JF, Ahrens CL, Tyburski JG, Wilson RF. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma 2005; 58:646-651.
86. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57:709-718.
87. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52:400-405.
88. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51:431-438.
89. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354:1879.
90. Harrison TD, Laskosky J, Jazaeri O, et al. 'Low-dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma 2005; 59:150-154.
91. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298. This important study examined reported adverse events for labeled and unlabelled uses of FVIIa using the Food and Drug Administration's Adverse Event Reporting System.
92. Fortune JB, Feustel PJ, Saifi J, et al. Influence of hematocrit on cardiopulmonary function after acute hemorrhage. J Trauma 1987; 27:243-249.
93. Topley E, Fisher MR. The illness of trauma. Br J Clin Pract 1956; 770-776.
94. Carson JL, Hill S, Carless P, et al. Transfusion triggers: a systematic review of the literature. Transfus Med Rev 2002; 16:187-199.
95. McIntyre L, Hebert PC, Wells G, et al. Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? J Trauma 2004; 57:563-568; discussion 568.
96. McIntyre LA, Fergusson DA, Hutchison JS, et al. Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury. J Neurocrit Care 2006; 5:4-9.
97. Chesnut RM. Secondary brain insults after head injury: clinical perspectives. New Horizons 1995; 3:366-375.
98. Jones PA, Andrews PJ, Midgley S, et al. Measuring the burden of secondary insults in head-injured patients during intensive care. J Neurosurg Anesthesiol 1994; 6:4-14.
99. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993; 34:216-222.
100. Chesnut RM, Gautille T, Blunt BA, et al. Neurogenic hypotension in patients with severe head injuries. J Trauma 1998; 44:958-963.
101. Winchell RJ, Simons RK, Hoyt DB. Transient systolic hypotension. A serious problem in the management of head injury. Arch Surg 1996; 131:533-539.
102. Chesnut RM, Marshall SB, Piek J, et al. Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the Traumatic Coma Data Bank. Acta Neurochir Suppl (Wien) 1993; 59:121-125.
103. Wald SL, Shackford SR, Fenwick J. The effect of secondary insults on mortality and long-term disability after severe head injury in a rural region without a trauma system. J Trauma 1993; 34:377-381.
104. Pigula FA, Wald SL, Shackford SR, Vane DW. The effect of hypotension and hypoxia on children with severe head injuries. J Pediatr Surg 1993; 28:310-314.
105. Marmarou A, Anderson RL, Ward JD, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg 1991; 75:S59-S66.
106. Miller JD, Butterworth JF, Gudeman SK, et al. Further experience in the management of severe head injury. J Neurosurg 1981; 54:289-299.
107. Price DJ, Murray A. The influence of hypoxia and hypotension on recovery from head injury. Injury 1972; 3:218-224.
108. Stocchetti N, Furlan A, Volta F. Hypoxemia and arterial hypotension at the accident scene in head injury. J Trauma 1996; 40:764-767.
109. Kokoska ER, Smith GS, Pittman T, Weber TR. Early hypotension worsens neurological outcome in pediatric patients with moderately severe head trauma. J Pediatr Surg 1998; 33:333-338.
110. Fearnside MR, Cook RJ, McDougall P, McNeil RJ. The Westmead Head Injury Project outcome in severe head injury. A comparative analysis of prehospital, clinical and CT variables. Br J Neurosurg 1993; 7:267-279.
111. DeWitt DS, Prough DS, Taylor CL, et al. Regional cerebrovascular responses to progressive hypotension after traumatic brain injury in cats. Am J Physiol 1992; 263 (4 Pt 2):H1276-H1284.
112. Glass TF, Fabian MJ, Schweitzer JB, et al. Secondary neurologic injury resulting from nonhypotensive hemorrhage combined with mild traumatic brain injury. J Neurotrauma 1999; 16:771-782.
113. Laks H, Pilon RN, Klovekorn WP, et al. Acute hemodilution: its effect on hemodynamics and oxygen transport in anesthetized man. Ann Surg 1974; 180:103-109.
114. Gibson JB, Maxwell RA, Schweitzer JB, et al. Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute. Shock 2002; 17:234-244.
115. West MA, Shapiro MB, Nathens AB, et al. Guidelines for transfusion in the trauma patient. J Trauma 2006; 61:436-439.